Goldberg R M, Loprinzi C L, O'Fallon J R, Veeder M H, Miser A W, Mailliard J A, Michalak J C, Dose A M, Rowland K M, Burnham N L
Geisinger Clinical Oncology Program, Danville, PA.
J Clin Oncol. 1994 Jan;12(1):155-8. doi: 10.1200/JCO.1994.12.1.155.
To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer.
A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study.
Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot-flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05).
Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.
确定透皮可乐定对缓解有乳腺癌病史女性的他莫昔芬诱发潮热的疗效。
本前瞻性研究采用随机、双盲、交叉设计。有乳腺癌病史且正在接受他莫昔芬治疗并患有潮热的女性有可能符合本方案研究的条件。
可乐定确实将潮热频率降低到了具有统计学意义的程度（P < .0001），但在临床上仅为中度降低（较基线降低20%）。它还降低了潮热严重程度（P = .02，较基线降低10%）。可乐定与口干增加（P < .001）、便秘（P < .02）、贴片下瘙痒（P < .01）和嗜睡（P < .05）有关。
需要更好的方法来缓解雌激素治疗禁忌患者的潮热。
